Upon receiving approval for ‘Steqeyma IV,’ a biosimilar version of the autoimmune disease treatment Stelara (ustekinumab), Celltion has now received approval for all its Steqeyma formulations.

By adding the interleukin (IL) inhibitor option to the existing family of tumor necrosis factor (TNF)-α inhibitors, which includes Remsima, Remsima SC, and Yuflyma, the company has strengthened its autoimmune disease portfolio.

On the 27th, the Ministry of Food and Drug Safety (MFDS) approved Celltrion's Steqeyma IV. Celltrion received approval for the prefilled syringe-type subcutaneous (SC) formulation of the same drug in June for the treatment of autoimmune diseases such as plaque psoriasis,